Novel safe GR-targeted therapy for hematological malignancies

Project: Research project

Project Details


Glucocorticoids (Gcs) have been widely and successfully used to treat a broad spectrum of hematological malignancies, and the glucocorticoid receptor (GR) is a well-known anti-cancer target. Unfortunately, most patients chronically treated with Gcs develop numerous deleterious metabolic and atrophic side effects that strongly affect the quality of their life. Thus, there is a great need for the development of safer GR-targeted therapies.
Effective start/end date1/23/177/22/20


  • ILSI Health and Environmental Sciences Institute (Agreement 12/05/16)


Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.